Gremminger Hearing Record Statement for 340B Drug Pricing Program

On Tuesday, June 4, the House Energy and Commerce Oversight and Investigations subcommittee hosted a hearing to discuss the 340B Drug Pricing Program. 

National Alliance President and CEO Shawn Gremminger submitted a written statement for the hearing record to provide the employer perspective on the impact of the unconstrained growth of the 340B drug pricing program on commercial purchasers and the need for greater oversight and significant reform.

Shawn’s statement is available by clicking the link below.